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Abstract. Cytogenetic studies in squamous cell carcinoma of 
the head and neck (SCCHN) have identified a clustering of 
breakpoints in a number of chromosomes, including 
chromosome 3. We have undertaken a loss of heterozygosity 
analysis (LOH) of 36 SCCHN and six solid tumours which 
were not squamous cell, and their respective normal 
specimens, using a bank of microsatellite markers, with the 
aim of identifying specific sites of frequent loss on 
chromosome 3. The analysis was undertaken with 12 
microsatellite markers, 10 of which are on the ρ arm of 
chromosome 3. Allelic loss greater than 10% was seen at 
four sites; D3S1269 (13%), D3S1079 (23%), D3S659 (23%) 
and D3S1293 (31%). None of this series of tumours showed 
loss of the whole chromosome, however 47% of the tumours 
analysed had LOH at one or more loci. The highest incidence 
of LOH was found at D3S1293 in the 3p24-p25 region. The 
second highest region with LOH was found at D3S1079 and 
D3S659 at 3pl3. The remaining markers telomeric and 
centromeric to these two regions were found to have a LOH 
of less than 10%. Furthermore, we found a strong association 
between loss of one marker on chromosome 3 in these 
SCCHN and poor clinical prognostic indicators; such as site, 
pathological differentiation, positive nodes at pathology 
(p<0.05) and TNM status (p<0.05). This study has identified 
two regions in SCCHN that are most likely to be important in 
the development of squamous cell carcinoma of the head and 
neck at 3p24-p25 and 3pl3 and may indicate sites of novel 
tumour suppressor genes in this disease. 
Introduction 
Loss of heterozygosity (LOH) for polymorphic DNA 
markers have already provided a wealth of information on 
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chromosomal imbalances which would have been difficult if 
not impossible to obtain from cytogenetic evidence 
(reviewed by Lasko et al; 1). Specific sites of frequent allele 
loss has been described in a number of malignancies such as; 
carcinomas of the colon (2,3), ovarian (4-6), colorectal, 
bladder (7-8), and breast carcinomas (9) and tumour 
suppressor genes (TSG) have been suggested to be involved 
at many of these regions. 
Cytogenetic studies in squamous cell carcinoma of the 
head and neck SSCHN has identified a clustering of 
breakpoints in a number of chromosomes, including 
chromosome 3. Jin et al (10) found a high incidence of 
chromosomal breakpoints at lp22 and l lq l3, whereas other 
groups have found lp36, 9q32, llq23, (11) 3p, 8q, lOp, 18q, 
(12), 3pl3-14, 8p21-23 and 18q21-23 (Van Dyke DL, 
Worsham MJ, Benninger MJ and Carney TE: 5th 
International Workshop on chromosomes in solid tumours, 
Arizona, 1993). However, there are many limitations to the 
interpretation of cytogenetic analysis of head and neck 
cancers as the majority of the chromosomes have been found 
to be involved (10,11). Latif et al (13) have used a bank of 
restriction fragment length polymorphism (RFLP) probes, 
and generated a 3p allelotype for 18-26 SSCHN cell lines. 
Their observations indicated that there was a commonly 
deleted region on 3p which lies telomeric to 3pl4 and 
centromeric to 3p25. Furthermore, in a cytogenetic analysis 
of 15 laryngeal tumours, a deletion in 3p was found in 60% 
of the cases analysed (14). This region of the chromosome 
has received a great deal of interest in a number of 
malignancies resulting in the mapping of the Von Hippel-
Lindau TSG to 3p25-26, small cell lung carcinoma genes to 
3p23-p21, non-small cell carcinoma gene to 3pl4, uterine 
cervix gene to 3pl4-p21 and renal cell carcinomas to 3pl4.2 
(15). 
The development of banks of microsatellite markers has 
now advanced the analysis of LOH studies (16,17). The 
microsatellites constitute one of the most abundant classes of 
repetitive DNA families in the human genome with 
approximately 100,000-150,000 (CA)
n
 repeats, and have 
been used extensively in linkage analysis (18) and are 
probably more sensitive than RFLP analysis. 
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We have investigated chromosome 3 in SCCHN with 12 
microsatellite markers in order to determine the incidence of 
LOH especially on the ρ arm of chromosome 3 and evaluate 
the results with the clinicopathological data. 
Materials and methods 
Forty-two tumour specimens were collected from patients 
with carcinomas of the head and neck by the Royal Liverpool 
Hospital, Department of Otorhinolaryngology (36 SCCs; 
hypopharynx (18), larynx (11), oropharynx (4) oral (2), and 2 
basal cell carcinomas, a malignant salivary tumour, a 
Warthins tumour, a chondroma and a neurosarcoma were 
selected for this study. Tumour samples obtained from 
surgical specimens were frozen in liquid nitrogen and stored 
at -70°C. 
Frozen sections were taken from representative parts of 
the tumour and stained with haematoxylin and eosin and the 
percentage of tumour to normal tissue was recorded. All 
tumour specimens used in this study contained more than 
50% tumour tissue compared with normal tissue. Clinico­
pathological and survival data was available for the majority 
of the patients investigated in this study. 
DNA extraction. Genomic DNA was extracted from tumour 
specimens using the Nucléon II DNA extraction kit from 
Scotlab, following the manufacturers instructions. Genomic 
DNA samples were stored at 4°C. 
Microsatellite repeat primers. The markers used in this study 
are shown in Table I. and their chromosomal location in Fig. 1. 
The Weissenback markers have been localised on the genetic 
map using all available published data to date. The 
microsatellite primers D3S1261, D3S1266, D3S1269, 
D3S1289, D3S1293, D3S1340 were obtained from Research 
Genetics, USA; D3S966, D3S1067, D3S1079 from the UK 
Human Genome Mapping Project; D3S1284 from Professor 
P. Humpheries University of Dublin; D3S659, RHO from Dr 
Pamela H. Rabbitts, University of Cambridge. The annealing 
temperature for each marker is given in Table I. Details of 
the microsatellite primers are available in the Genome Data 
Base, John Hopkins University, USA and from the UK 
Human Genome Mapping Project Research Centre, and 
Jones et al (19). 
LOH analysis. PCR reactions were performed in a 50 μΐ 
reaction volume and contained 200 ng of genomic DNA, 500 
μΜ dNTP, 10 pmoles of each forward and reverse 
microsatellite primers, 0.5 units of Taq DNA polymerase 
(Advanced Biotechnologies), 5 μΐ of 10X PCR Buffer (670 
mM Tris.HCl, pH 8.5; 166 mM ammonium sulphate; 67 mM 
magnesium chloride; 1.7mg/ml BSA; 100 μΜ ß-
mercaptoethanol; 1% (w/v) Triton X-100). The reactions were 
denatured for 4 minutes and the DNA was subsequently 
amplified for 25 cycles of 94°C for 30 seconds, the 
appropriate primer annealing temperature (Table I) for 30 
seconds and 72°C for 1 minute. 10 μΐ of the amplified PCR 
reaction mixture was electrophoresed overnight on a 10% 
acrylamide gel at 20 mA for 2500V h. The acrylamide gels 
were silver-stained and the DNA bands observed over a light 
box. 
Statistical analysis. Quantative data were analysed by X2 or 
Fisher's exact test where appropriate. Survival curves were 
drawn up using the Kaplan-Meier product limit estimate (20). 
Differences between survival times were analysed by the log 
rank method (21). 
Results 
We analysed 36 SCCHN and 6 non squamous tumours from 
the head and neck regions for LOH at 10 different loci on 
chromosome 3p and 2 loci on 3q using PCR microsatellite 
pairs. The LOH results are shown in Table II for all the 
patients (Pts) analysed, and the LOH frequencies at each 
locus are shown in Table III. Loss of heterozygosity is 
demonstrated in Pt. 343 at the D3S1293, D3S966, D3S1067 
and D3S1079 loci; heterozygous at the D3S1304 and 
D3S1269 loci and homozygous at the RHO locus (Fig. 2). 
Allele loss greater than 10% was seen at four loci, 
D3S1269 (13%, 4/30); D3S1079 (23% 5/22); D3S659 
(23%/6/26) and D3S1293 (31% 9/29). In this series of. 
SCCHN, none of the tumour specimens showed whole 
chromosome loss, however 47% (17/36) of the tumours 
analysed had LOH at one or more loci. 
The highest incidence of loss of heterozygosity was found 
at D3S1293 (31%) in the 3p24-25 region. No LOH was 
found at D3S1266 in 36 specimens of SCCHN, which has 
been localised to the 3p24 region centromeric to D3S1293. 
The Weissenbach et al, 1992 map indicates a 9cM distance 
between these two microsatellite markers. It is improbable 
that there is a large deletion at this site, as only two of these 
patients (327, 341) had LOH at D3S1289, which is 30cM 
centromeric to D3S1293. It is of note that in five cases (Pts. 
217, 327, 338, 343, 347) there is also loss at D3S1079 as 
well as D3S1293 and both of these markers are located at 
3pl3. Futhermore, the D3S1304 marker is 19cM telomeric to 
D3S1293 and only 7% of the SCCHN specimens had LOH at 
this locus. 
The clinicopathological data has been analysed in 
conjunction with the LOH results, for site, TNM stage, 
histological differentiation, positive nodes at pathology and 
survival. A clear association has been found between LOH 
on chromosome 3 and squamous cell carcinoma (SCC) at the 
hypopharyngeal site 58% (11/19), compared to 36% (4/11) 
LOH at the laryngeal site. Furthermore, an association 
between LOH on chromosome 3 and a poor clinical 
prognosis as judged by the level of differentiation, positive 
nodes at pathology and TNM staging has been found (Tables 
IV and V). 
Analysis of LOH on chromosome 3 and histological 
differentiation demonstrated an increase in the incidence of 
allelic loss with the level of differentiation; well differentiated 
20%, moderately differentiated 48% and poorly differentiated 
squamous cell carcinoma 83%, but this was not found to be 
statistically significant as the numbers of patients in certain 
groups were small (p> 0.05). However, a dramatic increase in 
the number of positive nodes at pathology was seen to 
correlate with LOH; SCCHN with no lymph nodes had 21% 
LOH, whereas SCCHN with positive lymph nodes had 63% 
LOH (p< 0.05). This trend with LOH on chromosome 3 with 
poor prognostic factors is further supported by an association 
with TNM staging of the tumours. Stages I, II, III had 33% 
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Figure 1. A karyogram of chromosome 3. The microsatellite marker loci are 
shown adjacent to their approximate map position based on previously 
published data and the LOH analysis in this study. 
(7/22) LOH compared to Stage IV, which had 77% (10/13) 
LOH (p<0.05). No correlations with survival data was found, 
however the follow-up for a number of these patients has been 
less than six months. 
Six other solid tumours of the head and neck region which 
were not squamous cell were also investigated and only one 
of these, a BCC had LOH at one locus (results not shown). 
Discussion 
In this study we have investigated loss of heterozygosity in 
36 SCCHN tumour specimens on chromosome 3 using a 
bank of microsatellite markers, the majority of which are on 
the 3p arm. We have identified one region with a high LOH 
(31%) using the D3S1293 marker which is located in the 
3p24-25 region. In view of the fact that the markers 
centromeric (D3S1266) and telomeric (D3S1304) to 
D3S1293 were found to have low LOH, argues strongly in 
favour of this locus being a possible site of a novel tumour 
suppressor gene in SCCHN. 
A region on chromosome 3p, 3pl4 (D3S3) to 3p25 
(RAFl) has been previously identified in SCCHN cell lines 
to have high allelic loss (13). These authors used novel 
statistical analysis to determine the importance of LOH on 
3p. They generated an SCCHN alleotype of 3p using a 
number of SCCHN cell lines with RFLP markers and then 
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Figure 2. LOH on chromosome 3, detected by PCR analysis of 
microsatellite loci in tumour 343, seven of the microsatellite markers are 
shown in this figure; D3S1304 heterozygous, D3S1293 LOH, D3S966 
LOH, D3S1067 LOH, D3S1079 LOH, D3S1269 heterozygous, RHO 
homozygous. Note the examples of a heteroduplex band (top band) and the 
stutter bands seen for both the alleles in D3S1067. 
546 FIELD et al: ALLELE LOSS IN CHROMOSOME 3 IN SCCHN 
Table I. Microsatellite repeat primers used in this study of loss of heterozygosity on chromosome 3 in head and neck 
squamous cell carcinomas. 
Microsatellite primers Map position Futher information on map position* Annealing temperature 
D3S1304W 
D3S1293W 
D3S1266W 
D3S1289W 
D3S1261 
D3S966 
D3S1067 
D3S1079 
D3S659 
D3S1284 
D3S1269W 
3p25-pter 
3p24-p25 
3p24 
[3p24]-[3p21.2-pl3] 
3p21.2-pl3 
3p21 
3pl4.3-p21.1 
3pl3 
3pl3 
3pl2-pl3 
3q 
RHO 3q21-q24 
19 cM telomeric from D3S1293 
located telomeric to pBH302-H/THRB. 
9cMfromD3S1266 
in region of CRI-R59-M/D3S12 
located midway between CRI-R59-M/3S12 
and CRI-R95-M/D3S13 21 cM centromeric 
from D3S1266 
in the region of CRI-C17-M/D3S20 
7cM from RHO 
55°C 
55°C 
55°C 
62°C 
63°C 
60°C 
60°C 
60UC 
50°C 
58°C 
57°C 
50°C 
*Information taken from Weissenbach et al 1992; wWeissenbach marker set (17). 
compared the average heterozygosity computed for these loci 
in randomly chosen individuals from a natural population, 
with the observed heterozygosity of the tumour cell DNAs. 
They firstly deduced that there was a general LOH in the 
SCCHN cell lines, and then estimated the loss for each 
individual locus, thereby delimiting the commonly deleted 
region. A synopsis of their findings are shown in Table VI. 
It is of note that they found the probability of the markers at 
3p24-25, D3S588 and THRB in the SCCHN cell lines 
(having the same heterozygosity as in normal individuals) to 
have values of 4xl0 1 0 and 0.0003, respectively. Our results 
substantiate these findings, as the D3S1293 (3p24-25) 
marker is located telomeric to THRB on the Weissenbach 
map, therefore it is most likely closely linked to the D3S588 
RFLP marker. In addition, a number of markers centromeric 
to THRB and telomeric to D3S3 also had high probabilities 
of loss in tumour DNA and Latiff et al (13) defined the 
whole 3pl3-p25 region of particular importance in SCCHN. 
The results reported in this study are in agreement with the 
findings of Latiff et al, as our LOH data indicates that there 
are specific LOH regions at 3p24-25 and also at 3pl3. Both 
of the markers D3S1079 and D3S659 located at 3pl3 
demonstrated a LOH of 23%. However, the intervening 
markers between D3S1293 (3p24-25) and the 3pl3 markers 
all had LOHs of less than 10%, which may be considered 
background LOH in tumour specimens. Even though many 
of the Weissenback markers have not been precisely located 
to the genetic map, Fig. 1 provides a reasonable assessment 
of their relative positions based on previously published data 
and the LOH analysis results in this study. 
A further argument for the presence of two putative TSGs 
on 3p comes from our clinical correlations with LOH 
analysis on chromosome 3. The clinicopathological 
parameters used to assess patients outcome were recorded for 
all of the patients investigated in this study. The most 
important are site, pathological differentiation, positive nodes 
at pathology and the TNM status of the tumour at diagnosis. 
All of these parameters were found to be associated with 
LOH on chromosome 3. SCCHN at the hypopharyngeal site 
constituted the largest group of patients studied, of whom 
58% (11/19) had lost one or more markers on chromosome 3, 
compared with the laryngeal tumours which had 36% LOH 
(4/12) on one or more markers on chromosome 3. 
Furthermore, the clinical prognosis of SCC at the hypo­
pharyngeal site is considered to have a worse prognosis than 
the larynx (22). 
The candidate genes for 3p24 and 3pl3 sites are listed in 
Table VII, these include CCK, ACT14, IL5RA, RAF1, 
FRA3A, IMPDH2, THRB, RARB, TOP2B, and RAB5 in the 
3p24-pter region. Recent evidence indicates that there may 
be as many as three TSGs on the ρ arm of chromosome 3. 
Hibi et al (23) have shown that there are three distinct 
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Table II. An analysis of 36 SCCHN by PCR microsatellite primers. 
H H H H H H H H H H H H H H H H H H H 
03S1304 
D3S1293 
D3S1266 
D3S1289 
D3S1261 
D3S966 
D3S1067 
D3S1079 
03S659 
D3S1284 
D3S1269 
HHO 
114 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
128 
Ο 
0 
0 
0 
0 
0 
c 
0 
0 
0 
0 
0 
184 
Ο 
• 
Ο 
Ο 
Ο 
• 
a 
0 
• 
192 
0 
0 
0 
0 
0 
Û 
0 
• 
0 
218 
υ 
Ο 
0 
• 
Ο 
0 
ο 
ο 
224 
G 
C 
Ο 
0 
C 
G 
G 
0 
0 
G 
0 
0 
227 
• 
G 
e 
0 
C' 
• 
3 0 2 
0 
0 
0 
0 
e 
e 
0 
0 
0 
G 
G 
0 
3 1 0 
0 
G 
• 
0 
0 
û 
G 
0 
313 
G 
0 
Ο 
Ο 
Ο 
Ο 
0 
G 
Ο 
Ο 
Ο 
Ο 
314 
0 
0 
Ο 
0 
0 
e 
0 
0 
• 
0 
0 
0 
324 
0 
Ο 
0 
0 
0 
0 
0 
• 
0 
0 
0 
3 2 5 
Ο 
Ο 
Ο 
0 
Ο 
0 
Ο 
• 
• 
Ο 
Ο 
Ο 
329 
• 
• 
Ο 
Ο 
Ο 
Ο 
0 
0 
0 
0 
0 
0 
3 3 6 
0 
Ο 
Ο 
Ο 
Ο 
Ο 
Ο 
0 
Ο 
Ο 
Ο 
0 
338 
Ο 
• 
0 
0 
G 
0 
Ο 
• 
0 
0 
0 
0 
3 4 0 
Ο 
G 
0 
0 
Ο 
G 
C; 
G 
341 
• 
• 
Ο 
• 
0 
Ο 
0 
0 
Ο 
• 
Ο 
3 4 6 
Ο 
Ο 
0 
Ο 
0 
G 
0 
• 
Ο 
Ο 
0 
L L L L L L L L L L L M M M M 0 0 
315 
Ο 
0 
Ο 
Ο 
0 
0 
Ο 
0 
0 
0 
327 
0 
• 
Ο 
• 
0 
0 
Ο 
• 
0 
0 
0 
0 
3 4 2 
0 
0 
0 
0 
0 
0 
0 
G 
0 
Ο 
Ο 
0 
3 4 8 
Ο 
0 
Ο 
0 
Ο 
Ο 
Ο 
Ο 
0 
0 
0 
D3S1304 
D3S1293 
D3S1266 
03S1289 
D3S1261 
D3S966 
D3S1067 
D3S1079 
D3S659 
D3S1284 
D3S1269 
RHO 
41 
0 
G 
G 
G 
C' 
G 
0 
G 
0 
0 
G 
Ο 
76 
• 
G 
G 
• 
0 
0 
132 
G 
Ο 
Ο 
Ο 
Ο 
• 
0 
2 0 2 
Ο 
Ο 
Ο 
Ο 
Ο 
Ο 
Ο 
Ο 
0 
Ο 
2 1 3 
Ο 
G 
Ο 
Ο 
Ο 
Ο 
Ο 
0 
0 
Ο 
215 
Ο 
G 
0 
Ο 
Ο 
Ο 
Ο 
0 
0 
Ο 
Ο 
0 
217 
• 
0 
0 
0 
0 
0 
• 
• 
0 
• 
2 2 3 
Ο 
Ο 
G 
Ο 
G 
C 
0 
0 
0 
0 
0 
Ο 
225 
G 
Ο 
G 
Ο 
Ο 
G 
0 
3 1 8 
Ο 
0 
Ο 
0 
Q 
0 
G 
Ο 
G 
G 
Ο 
Ο 
347 
0 
• 
0 
0 
0 
0 
0 
• 
G 
0 
0 
0 
201 
Ο 
Ο 
Ο 
Ο 
0 
Ο 
0 
Ο 
Ο 
Ο 
343 
Ο 
• 
Ο 
0 
G 
• 
• 
• 
0 
Ο 
Ο 
0 
The symbols used are: · , constitutional heterozygosity with loss of heterozygosity; o, constitutional heterozygosity with no loss of 
heterozygosity; 0, homozygous; not done/not determined; 0. oropharynx; H, hypopharynx; L, larynx and M, oral cavity. 
Table III. Loss of heterozygosity on chromosome 3 in head and neck squamous cell carcinomas. 
Chromosome location Microsatellite primers Number of patients analysed Allelic loss/ 
informative cases (% LOH) 
3p25-pter 
3p24-p25 
3p24 
3p24-pl3 
3p21.2-pl3 
3p21 
3pl4.3-p21.1 
3pl3 
3pl3 
3pl2-pl3 
3q 
3q21-q24 
D3S1304 
D3S1293 
D3S1266 
D3S1289 
D3S1261 
D3S966 
D3S1067 
D3S1079 
D3S659 
D3S1284 
D3S1269 
RHO 
24 
33 
36 
36 
36 
36 
28 
31 
30 
29 
31 
24 
2/23 (7) 
9/29(31) 
0/36 (0) 
3/33 (9) 
2/33 (6) 
2/28 (7) 
1/17 (6) 
5/22 (23) 
6/26 (23) 
0/27 (0) 
4/30(13) 
0/14 (0) 
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Table IV. Loss of heterozygosity on chromosome 3 with TNM staging. 
Stage 
I 
II 
III 
IV 
Loss of one or 
two markers 
2 
0 
3 
7 
Loss of 3 or 
more markers 
0 
0 
2 
3 
No lo 
5 
1 
10 
3 
LOH/ Heterozygous Percent 
2/7 
0/1 
5/14 
10/13 
28 
33 
77 
Stages I, II, III with IV, ρ = 0.006 
Table V. Loss of heterozygosity on chromosome 3 with histological differentiation and positive nodes at pathology. 
Loss of one or more 
markers on chromosome 3 No loss Percentage 
Histology: 
well differentiated 
moderately differentiated 
poorly differentiated 
positive nodes at pathology: 
no nodes 
positive nodes 
1 
10 
5 
3 
10 
4 
1 
1 
20 
48 
83 
11 
6 
21 
63 
(p>0.05) 
(p<0.05) 
Table VI. Chromosome 3p deletions in head and neck cell 
lines.3 
Location on 3p 
3p25 
3p25 
3p24-25 
3p24 
3p21-p24 
3p21-p24 
3p21 
3pl4-p21 
3pl4.2-p21 
3pl3 
3pl3 
Locus 
D3S571 
RAF 
D3S588 
THRB 
D3S734 
D3S232 
D3F15S2 
D3S32 
D3S2 
D3S642 
D3S3 
Probability* 
0.0038 
0.0009 
4xl0 1 0 
0.0003 
4xl0-5 
0.0022 
lxlO 7 
8xl0"5 
9xl0-6 
4xl0"5 
0.1307 
adata from Latif et al (13); Probability that 3p loci in tumour DNA 
have the same heterozygosity as that of the normal population. *all 
significant at the 0.0023 level. 
regions in lung cancer, 3p25, 3p21.3 and 3pl4. Moreover, 
the 3pl4 region has been further defined in lung cancer by 
Yamakawa et al (24), and the 3pl3-p21.1 region has been 
identified in uterine-cervical cancer (25) as a site of a 
putative TSG. 
This study has identified two regions in SCCHN that are 
probably important in the development of squamous cell 
carcinoma of the head and neck (3p24-p25, 3pl3), however, 
a larger number of patients will have to be studied with a 
bank of specific markers in these regions to determine their 
importance. 
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